Publications by authors named "C G Peterfy"

Claim this Profile
L
Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN study.
Andrew J Wagner, William D Tap, Sebastian Bauer, Jean-Yves Blay, Jayesh Desai, Charles Peterfy

Oncologist· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study.
Roy Fleischmann, Jerzy Swierkot, Sara K Penn, Patrick Durez, Louis Bessette, Charles G Peterfy

RMD Open· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 program.
Charles G Peterfy, Vibeke Strand, Alan Friedman, Stephen Hall, Eduardo Mysler

Rheumatology (Oxford)· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CSF1 receptor inhibition of tenosynovial giant cell tumor using novel disease-specific MRI measures of tumor burden.
Charles Peterfy, Yan Chen, Peter Countryman, Bartosz Chmielowski, Stephen P Anthony

Future Oncol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study.
Roy Fleischmann, Eduardo Mysler, Louis Bessette, Charles G Peterfy, Patrick Durez

RMD Open· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis